(118 days)
No
The description focuses on the mechanical and electrical processing of sound and does not mention any AI/ML components or capabilities.
Yes
The device is intended to compensate for conductive hearing loss, mixed hearing loss, or single-sided sensorineural deafness (SSD) by mechanically vibrating the skull bone and cochlea, which is a therapeutic function.
No
The Osia System is a hearing aid that converts sound into vibrations to compensate for hearing loss. It is a therapeutic device designed to improve hearing, not to diagnose a condition. The "Intended Use" section clearly states its purpose as sound amplification for patients with specific types of hearing loss.
No
The device description clearly outlines multiple hardware components including a surgically implanted receiver/coil and actuator/stimulator, an external sound processor, and an implant fixed to the bone. While there is fitting software mentioned, the system is not solely software.
Based on the provided text, the Osia System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: IVD devices are used to examine specimens (like blood, urine, or tissue) taken from the human body to provide information about a person's health.
- Osia System Function: The Osia System is a surgically implanted and external device that mechanically vibrates the skull bone to compensate for hearing loss. It directly interacts with the patient's body to improve hearing, rather than analyzing a sample taken from the body.
- Intended Use: The intended use clearly describes treating hearing loss in specific patient populations.
- Device Description: The description details the mechanical and electrical components that work together to transmit sound vibrations. There is no mention of analyzing biological samples.
Therefore, the Osia System falls under the category of a medical device, specifically a hearing implant system, and not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Osia System is intended for the following patients and indications:
· Patients 12 years of age or older.
· Patients who have a conductive or mixed hearing loss and still can benefit from sound amplification. The pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2, and 3 kHz) should be better than or equal to 55 dB HL.
· Bilateral fitting of the Osia System is intended for patients having a symmetrically conductive or mixed hearing loss. The difference between the left and right sides' BC thresholds should be less than 10 dB on average measured at 0.5, 1, 2, and 3 kHz, or less than 15 dB at individual frequencies.
· Patients who have profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e., single-sided deafness or "SSD"). The pure tone average air conduction hearing thresholds of the hearing ear should be better than or equal to 20 dB HL (measured at 0.5, 1, 2, and 3 kHz).
· The Osia System for SSD is also indicated for any patient who is indicated for an airconduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.
· Prior to receiving the device, it is recommended that an individual have experience with appropriately fitted air conduction or bone conduction hearing aids.
Product codes
PFO
Device Description
The Osia 2 System, also known as Osia System, mechanically vibrates the skull bone and subsequently the cochlea to compensate for conductive hearing loss, mixed hearing loss, or single-sided sensorineural deafness (SSD).
The Osia 2 System is made up of several components. The Osia implant (OSI200) consists of a receiver/coil and an actuator/stimulator (vibrator) which is surgically implanted on the skull bone. The external component of the Osia 2 System is a sound processor, worn off-the-ear, which picks up the sound from the environment, and sends, after processing, the information to the implant via a transcutaneous inductive link. This link is also referred to as radiofrequency (RF) link. Each Osia 2 System is configured to meet an individual's hearing needs, using dedicated fitting software.
In normal operation, the Osia System functions as follows:
- The external sound processor captures and digitally processes sound.
- The sound processor transmits power and digital information to the implant coil/receiver.
- The implant stimulator/actuator converts the digital information into an electric analogue signal that is converted to vibrations by the implant piezoelectric actuator.
This implant is fixed to the bone by the BI300 implant (K100360). 4. The actuator converts the electrical signal into an amplified mechanical stimulation, bypassing the impaired middle ear (origin of the conductive part of the hearing loss) and providing some level of mechanical amplification in order to compensate for the damaged inner ear (sensorineural part of the hearing loss, in case of mixed hearing loss).
The updated Osia 2 System consists of modifications to the cleared OSI200 Implant, Osia 2 Sound Processor and Osia Fitting Software 2. All other components of the system remain unchanged from the cleared predicate.
The Cochlear MRI Kit is being introduced for use by Osia recipients. The MRI Kit is an accessory that enables an MR scan at 1.5T without the need to surgically remove a compatible Osia implant's magnet.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Mastoid region of either side of the head (for implant).
Head behind the ear (for sound processor).
Indicated Patient Age Range
12 years of age or older.
Intended User / Care Setting
Professional use only. The fitting software is used by the audiologist.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Bench testing was conducted to compare the updated Osia 2 System with the cleared Osia 2 System. Substantial equivalence to the predicate device was accomplished through non-clinical data related to functionality and performance testing, hardware and interface testing, as well as system and subsystem level testing.
Verification activities for the modified OSI200 Implant included performance testing re-executed to support:
- Functional verification
- Safety and Reliability verification related to Accelerated Life, Maximum Surface Temperature, Diagnostic Ultrasound, Therapeutic Ionising Radiation, ESD, High Power Electric Fields
- Environmental Testing verification
The following verification testing performed on the cleared OSI200 Implant remains applicable to the modified OSI200 Implant and were leveraged with justification from the predicate device.
- Fixation Screw verification
- Safety and Reliability verification related to Static and Cyclic Load, Impact, Robustness, Fluid Ingress, Release of Particulate Matter, Biological Safety, System EMC Compliance, MRI Safety
- Surgical Implementation
- Sterilization
- Sterile Barrier
- Shelf-Life
Validation activities re-executed for the OSI200 Implant were limited to Intended Implant Lifetime. Validation for the Osia 2 System included tests re-executed to validate the functionality and performance of the updated system.
The Cochlear MRI Kit underwent verification testing of the MRI Kit when used at 1.5T with Osia implants, and undergone summative usability testing to evaluate the usability of the MRI Kit and accompanying documentation by specialized healthcare professionals.
The results demonstrate the updated Osia 2 System, including the modified OSI200 Implant, Osia 2 Sound Processor, and Osia Fitting Software 2 and new Cochlear MRI Kit, are functionally equivalent to the cleared Osia 2 System.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 874.3340 Active implantable bone conduction hearing system.
(a)
Identification. An active implantable bone conduction hearing system is a prescription device consisting of an implanted transducer, implanted electronics components, and an audio processor. The active implantable bone conduction hearing system is intended to compensate for conductive or mixed hearing losses by conveying amplified acoustic signals to the cochlea via mechanical vibrations on the skull bone.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Clinical performance testing must characterize any adverse events observed during implantation and clinical use, and must also demonstrate that the device performs as intended under anticipated conditions of use.
(2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including the following:
(i) Performance data must validate force output in a clinically relevant model.
(ii) Impact testing in a clinically relevant anatomic model must be performed.
(iii) Mechanical integrity testing must be performed.
(iv) Reliability testing consistent with expected device life must be performed.
(3) The patient-contacting components of the device must be demonstrated to be biocompatible.
(4) Performance data must demonstrate the sterility of the patient-contacting components of the device.
(5) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the identified shelf life.
(6) Performance data must demonstrate the wireless compatibility, electromagnetic compatibility, and electrical safety of the device.
(7) Software verification, validation, and hazard analysis must be performed.
(8) Labeling must include:
(i) A summary of clinical testing conducted with the device that includes a summary of device-related complications and adverse events;
(ii) Instructions for use;
(iii) A surgical guide for implantation, which includes instructions for imaging to assess bone dimensions;
(iv) A shelf life, for device components provided sterile;
(v) A patient identification card; and
(vi) A patient user manual.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
July 27, 2022
Cochlear Americas Samata Veluvolu Principal Regulatory Specialist 10350 Park Meadows Drive Lone Tree. Colorado 80124
Re: K220922
Trade/Device Name: Cochlear Osia 2 System, Cochlear Osia OSI200 Implant, Cochlear Osia 2 Sound Processor, Cochlear Osia Fitting Software 2, Cochlear MRI Kit Regulation Number: 21 CFR 874.3340 Regulation Name: Active implantable bone conduction hearing system Regulatory Class: Class II Product Code: PFO Dated: June 23, 2022 Received: June 24, 2022
Dear Samata Veluvolu:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies.combination product submissions. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
1
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrl-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Shu-Chen Peng, Ph.D. Assistant Director DHT1B: Division of Dental and ENT Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K220922
Device Name Cochlear™ Osia® 2 System
Indications for Use (Describe)
The Osia System is intended for the following patients and indications:
· Patients 12 years of age or older.
· Patients who have a conductive or mixed hearing loss and still can benefit from sound amplification. The pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2, and 3 kHz) should be better than or equal to 55 dB HL.
· Bilateral fitting of the Osia System is intended for patients having a symmetrically conductive or mixed hearing loss. The difference between the left and right sides' BC thresholds should be less than 10 dB on average measured at 0.5, 1, 2, and 3 kHz, or less than 15 dB at individual frequencies.
· Patients who have profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e., singlesided deafness or "SSD"). The pure tone average air conduction hearing thresholds of the hearing ear should be better than or equal to 20 dB HL (measured at 0.5, 1, 2, and 3 kHz).
· The Osia System for SSD is also indicated for any patient who is indicated for an airconduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.
· Prior to receiving the device, it is recommended that an individual have experience with appropriately fitted air conduction or bone conduction hearing aids.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| X Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image contains the logo for Cochlear, a company that specializes in hearing solutions. The logo features a stylized, golden-yellow graphic of three overlapping curved shapes, resembling sound waves or the inner ear. Below the graphic, the company name "Cochlear" is written in a matching golden-yellow color, with the registered trademark symbol to the right. Underneath the company name, the tagline "Hear now. And always" is displayed in a smaller font, emphasizing the company's commitment to long-term hearing solutions.
510(k) Summary
| A. Submitter Information | |
|---|---|
| Submitted by: | Cochlear Americas |
| 10350 Park Meadows Drive | |
| Lone Tree, CO 80124 | |
| On behalf of the manufacturer: | Cochlear Ltd – Macquarie |
| 1 University Avenue | |
| Macquarie University, NSW 2109 | |
| Australia | |
| (Establishment Number 9076254) | |
| Contact: | Samata Veluvolu |
| Principal Regulatory Specialist | |
| Cochlear Americas | |
| C: 302-542-6468 | |
| E: sveluvolu@cochlear.com | |
| B. Date Prepared | 26-July-2022 |
| C. Device Name and Classification | |
| Device Names: | Cochlear™ Osia® OSI200 Implant |
| Cochlear™ Osia® 2 Sound Processor | |
| Cochlear™ Osia® Fitting Software 2 | |
| Cochlear™ MRI Kit | |
| Trade/Proprietary Name: | Cochlear™ Osia® 2 System |
| Common/Usual Name: | Osia System |
| Classification Name: | Active implantable bone conduction hearing system |
| 21 CFR 874.3340, Class II | |
| Classification Panel: | Ear, Nose, and Throat |
| Product Code: | PFO |
| D. Predicate Device | |
| Device Names: | Cochlear™ Osia® OSI200 Implant |
| Cochlear™ Osia® 2 Sound Processor | |
| Cochlear™ Osia® Fitting Software 2 | |
| Trade/Proprietary Name: | Cochlear™ Osia® 2 System |
| Common/Usual Name: | Osia System |
4
Image /page/4/Picture/0 description: The image contains the logo for Cochlear, a company that specializes in hearing solutions. The logo features a stylized, golden-yellow graphic resembling a cochlea, the spiral-shaped part of the inner ear. Below the graphic, the company name "Cochlear" is printed in a matching golden-yellow color, with the registered trademark symbol next to it. Underneath the company name, the tagline "Hear now. And always" is displayed in a smaller font, emphasizing the company's commitment to long-term hearing solutions.
| Classification Name: | Active implantable bone conduction hearing system
21 CFR 874.3340, Class II |
|-----------------------|--------------------------------------------------------------------------------|
| Classification Panel: | Ear, Nose, and Throat |
| Product Code: | PFO |
| 510(k): | K191921 |
E. Purpose of Submission
This Traditional 510(k) seeks clearance for an updated Osia 2 System, which includes modifications to existing Osia 2 System components (the OSI200 Implant, Osia 2 Sound Processor and Osia Fitting Software 2) and requests clearance of a Cochlear MRI Kit accessory for use by Osia recipients. The second generation Osia 2 System (predicate), was cleared under K191921 on November 15, 2019.
F. Device Description
The Osia 2 System, also known as Osia System, mechanically vibrates the skull bone and subsequently the cochlea to compensate for conductive hearing loss, mixed hearing loss, or single-sided sensorineural deafness (SSD).
The Osia 2 System is made up of several components. The Osia implant (OSI200) consists of a receiver/coil and an actuator/stimulator (vibrator) which is surgically implanted on the skull bone. The external component of the Osia 2 System is a sound processor, worn off-the-ear, which picks up the sound from the environment, and sends, after processing, the information to the implant via a transcutaneous inductive link. This link is also referred to as radiofrequency (RF) link. Each Osia 2 System is configured to meet an individual's hearing needs, using dedicated fitting software. The Osia 2 System is illustrated in Figure 1 below.
Figure 1. Overview of the Osia 2 System, including the Osia 2 Sound Processor
Image /page/4/Picture/8 description: This image shows a medical implant device. The device consists of four labeled parts. Part 1 is a black electronic component that sits on top of the skin. Part 2 is a thin, flexible component that is implanted under the skin, and part 3 is a rigid component that is attached to the bone with a screw, labeled as part 4.
In normal operation, the Osia System functions as follows (referring to Figure 1):
-
- The external sound processor captures and digitally processes sound.
-
- The sound processor transmits power and digital information to the implant coil/receiver.
5
Image /page/5/Picture/0 description: The image shows the logo for Cochlear, a company that specializes in hearing solutions. The logo features a stylized, abstract representation of a cochlea, the spiral-shaped part of the inner ear, rendered in a golden color. Below the cochlea graphic, the company name "Cochlear" is written in a clear, sans-serif font, also in golden color. Underneath the company name, the tagline "Hear now. And always" is displayed in a smaller font size, emphasizing the company's commitment to providing long-term hearing solutions.
-
- The implant stimulator/actuator converts the digital information into an electric analogue signal that is converted to vibrations by the implant piezoelectric actuator.
- This implant is fixed to the bone by the BI300 implant (K100360). 4.
The actuator converts the electrical signal into an amplified mechanical stimulation, bypassing the impaired middle ear (origin of the conductive part of the hearing loss) and providing some level of mechanical amplification in order to compensate for the damaged inner ear (sensorineural part of the hearing loss, in case of mixed hearing loss).
The updated Osia 2 System consists of modifications to the cleared OSI200 Implant, Osia 2 Sound Processor and Osia Fitting Software 2. All other components of the system remain unchanged from the cleared predicate.
The Cochlear MRI Kit is being introduced for use by Osia recipients. The MRI Kit is an accessory that enables an MR scan at 1.5T without the need to surgically remove a compatible Osia implant's magnet.
G. Intended Use
The Cochlear Osia System uses bone conduction to transmit sounds to the cochlea (inner ear) with the purpose of enhancing hearing. Osia Implants are single use devices intended for long term implantation under the skin in the mastoid region of either side of the head. They are for professional use only.
H. Indications for Use
The Osia System is intended for the following patients and indications:
- Patients 12 years of age or older. ●
- Patients who have a conductive or mixed hearing loss and still can benefit from sound amplification. The pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2, and 3 kHz) should be better than or equal to 55 dB HL.
- . Bilateral fitting of the Osia System is intended for patients having a symmetrically conductive or mixed hearing loss. The difference between the left and right sides' BC thresholds should be less than 10 dB on average measured at 0.5, 1, 2, and 3 kHz, or less than 15 dB at individual frequencies.
- Patients who have profound sensorineural hearing loss in one ear and normal hearing in ● the opposite ear (i.e., single-sided deafness or "SSD"). The pure tone average air conduction hearing thresholds of the hearing ear should be better than or equal to 20 dB HL (measured at 0.5, 1, 2, and 3 kHz).
- . The Osia System for SSD is also indicated for any patient who is indicated for an airconduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.
- Prior to receiving the device, it is recommended that an individual have experience with ● appropriately fitted air conduction or bone conduction hearing aids.
6
Image /page/6/Picture/0 description: The image shows the logo for Cochlear, a company that specializes in hearing solutions. The logo features a stylized, abstract symbol in a golden color, resembling three nested, curved shapes. Below the symbol, the company name "Cochlear" is written in a clear, sans-serif font, also in golden color. Underneath the company name, the tagline "Hear now. And always" is displayed in a smaller font size, completing the logo.
I. MR Conditional
The Osia System's implants are MR conditional with the implant magnet in place with the use of a Cochlear MRI Kit at 1.5T or with the magnet removed at 1.5T and 3.0T. The MRI Kit is intended to prevent the dislodgement of implanted magnets in a hearing implant during a Magnetic Resonance Imaging (MRI) procedure.
The MRI Kit is indicated for hearing implant recipients who require an MR scan at 1.5T and have been assessed by medical professionals as suitable for an MR scan.
The MRI Kit is indicated for a recipient with the following compatible Osia implants:
- Osia OSI100 implant ●
- Osia OSI200 implant ●
J. Technological Characteristics and Comparison to Predicate
Like other active implantable bone conduction hearing systems, the Osia 2 System is comprised of multiple components, including: an implant, sound processor, fitting software, and other cables and accessories. The Osia 2 System is intended to compensate for conductive or mixed hearing loss or single sided deafness by conveying amplified acoustic signals to the cochlea via mechanical vibrations on the skull bone. These vibrations bypass the damaged parts of the outer and/or middle ear to stimulate the inner ear hair cells, allowing patients to clearly hear sounds and speech around them.
Both the updated Osia 2 System and the predicate Osia 2 System are surgically implanted in the mastoid bone, and an external sound processor is held in place on the patient's scalp by magnetic attraction between the implant and sound processor.
The updated Osia 2 System, which includes modifications to the cleared OSI200 Implant, Osia 2 Sound Processor and Osia Fitting Software 2, has the same intended use, the same overall functional characteristics, and the same fundamental operating principles as the predicate Osia 2 System. The updated Osia System introduces the MRI Kit as a new accessory for use with compatible Osia implants.
Table 1 summarizes a comparison of the technological characteristics of the currently available Osia 2 System (predicate device) with the updated Osia 2 System (subject device). Additional details related to the changes are provided below the table.
| Technological
Characteristic | Osia 2 System (Predicate,
K191921) | Osia 2 System (Subject) |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| Energy Used / Delivered | An external sound processor
is used to pick up surrounding
sound and transfer it to an
implant through a digital
inductive link. That implant
picks up the signal and
translates it into vibrations. A | Same |
| Table 1: Comparison Summary of Osia 2 System | ||||
|---|---|---|---|---|
| -- | ---------------------------------------------- | -- | -- | -- |
7
Image /page/7/Picture/0 description: The image contains the logo for Cochlear, a company that specializes in hearing solutions. The logo features a stylized, golden-yellow spiral shape resembling a cochlea, which is the auditory portion of the inner ear. Below the spiral is the company name, "Cochlear," also in golden-yellow. Underneath the name is the tagline, "Hear now. And always."
| Technological
| Characteristic | Osia 2 System (Predicate, K191921) | Osia 2 System (Subject) |
|---|---|---|
| second implant is screwed | ||
| into the bone (and | ||
| osseointegrates), and is | ||
| attached to the first implant, | ||
| ensuring implant anchoring | ||
| and that vibrations are | ||
| transferred to the cochlea. | ||
| System Compatibility | The Osia 2 System includes | |
| an implant, sound processor, | ||
| surgical tools and accessories, | ||
| software, programming cable, | ||
| and fitting software. |
It is also capable of wireless
connection to accessories and
the fitting software. | The Osia 2 System has the
same system compatibility
with the addition of the
Cochlear MRI Kit. |
| OSI200 Implant | The OSI200 Implant consists
of the following major
components: fixation screw,
lead/coil, actuator, stimulator,
and magnet. | Same, except the OSI200
Implant's printed circuit
assembly (PCA) has been
updated. |
| Osseointegrated Implant
Radiation Safety | BI300 (K100360) | Same |
| Radiation Safety | The Osia System is
compatible for use with x-ray,
CT scans, radiation therapy,
and PET.
The Osia System is MR
Conditional. | The Osia System is
compatible for use with x-ray,
CT scans, radiation therapy,
and PET.
The Osia System remains MR
Conditional; however, MR
Conditions have changed to
allow MR scans at 1.5T with
the implant magnet in place
with the use of a Cochlear
MRI Kit. |
| OSI200 Implant magnet
conditions for MRI | The OSI200 Implant is MR
conditional with the implant
magnet removed at 1.5T and
3.0T. | The OSI200 Implant is MR
conditional with the implant
magnet in place with the use
of a Cochlear MRI Kit at
1.5T, or removed at 1.5T and
removed at 3.0T. |
| Sound Processor | The Osia 2 System requires
the use of an externally worn
sound processor that is worn
on the head behind the ear | Same, except the Osia 2
Sound Processor firmware
(for the second block) is
updated with new |
| Technological
Characteristic | Osia 2 System (Predicate,
K191921) | Osia 2 System (Subject) |
| | | |
| | The Osia 2 Sound Processor's
main function is to receive
sound using its two
microphones, perform signal
processing and deliver power
and an audio stream to the
OSI200 implant via the RF
link.
The Osia 2 Sound Processor
chipset includes two distinct
blocks: one block is
responsible for receiving the
microphone input, performing
signal processing, and
delivering an analogue output
signal that is fed into the
differential input of the other
block. The second block is
responsible for transferring
the audio signal to the
implant via the RF link. | functionalities to support the
changes to the OSI200
Implant. |
| | | |
| Fitting Software | The Osia Fitting Software 2 is
used by the audiologist to
configure all patient related
data in the sound processor.
The fitting software is an
application running on a
Windows PC.
It is a stand-alone software | Same, except new features
are available in the Osia
Fitting Software 2 to support
the changes to the OSI200
Implant. |
8
Image /page/8/Picture/0 description: The image contains the logo for Cochlear, a company that specializes in hearing solutions. The logo features a stylized, golden-yellow spiral shape resembling a cochlea, which is the auditory portion of the inner ear. Below the spiral is the company name, "Cochlear," also in golden-yellow. Underneath the name is the tagline, "Hear now. And always."
Additional details on the new features and functionalities added to predicate components are provided below:
OSI200 Implant
- The Printed Circuit Assembly (PCA) quantization level setting has been updated. ●
- A power switch has been enabled to control the implant gain setting to reduce the noise ● floor, if required.
- New circuitry has been added to improve implant restart time when the implant resets due . to power supply being at critical voltages.
9
Image /page/9/Picture/0 description: The image contains the logo for Cochlear, a company that specializes in hearing solutions. The logo features three curved shapes stacked on top of each other, resembling a stylized ear or sound wave. Below the symbol is the company name, "Cochlear," in a bold, sans-serif font. Underneath the name is the tagline, "Hear now. And always."
Verification related to the OSI200 Implant was completed based on changes to the printed circuit assembly (PCA) and concluded that the PCA does not affect the safety and effectiveness of the device. See K. Performance Data for more details on bench testing completed.
Osia Fitting Software 2
- The updated software has the ability to detect the updated OSI200 Implant. ●
- Additional functionality has been added to activate the implant gain setting feature, if required.
Verification related to the Osia Fitting Software 2 was performed on a series of software builds which confirmed that the new functionalities added to the fitting software to allow it to detect the updated OSI200 implant and activate the gain setting do not affect safety and effectiveness of the device.
Osia 2 Sound Processor
- . The updated sound processor has the ability to detect the updated OSI200 Implant.
- . Additional functionality has been added to activate the implant gain setting feature, if required.
- Configured sleep mode in sound processor to improve system startup process. .
The Osia 2 Sound Processor hardware remains unmodified from the predicate device. Verification results related to the sound processor's firmware confirm that the new functionalities added to the sound processor firmware to allow it to detect the updated OSI200 implant and activate the gain setting do not affect safety and effectiveness of the device.
K. Performance Data
Bench testing was conducted to compare the updated Osia 2 System with the cleared Osia 2 System. Substantial equivalence to the predicate device was accomplished through non-clinical data related to functionality and performance testing, hardware and interface testing, as well as system and subsystem level testing.
Verification activities for the modified OSI200 Implant included performance testing re-executed to support:
- . Functional verification
- Safety and Reliability verification related to Accelerated Life, Maximum Surface ● Temperature, Diagnostic Ultrasound, Therapeutic Ionising Radiation, ESD, High Power Electric Fields
- Environmental Testing verification ●
The following verification testing performed on the cleared OSI200 Implant remains applicable to the modified OSI200 Implant and were leveraged with justification from the predicate device.
- Fixation Screw verification ●
- . Safety and Reliability verification related to Static and Cyclic Load, Impact, Robustness, Fluid Ingress, Release of Particulate Matter, Biological Safety, System EMC Compliance, MRI Safety
- Surgical Implementation
- Sterilization ●
- . Sterile Barrier
10
Image /page/10/Picture/0 description: The image is a logo for Cochlear, a company that specializes in hearing solutions. The logo features a stylized, golden-yellow graphic of three curved shapes nested within each other, resembling a cochlea. Below the graphic is the company name, "Cochlear," in a bold, sans-serif font, also in golden-yellow. Underneath the name is the tagline, "Hear now. And always.", in a smaller, lighter font.
- . Shelf-Life
Validation activities re-executed for the OSI200 Implant were limited to Intended Implant Lifetime. Validation for the Osia 2 System included tests re-executed to validate the functionality and performance of the updated system.
The Cochlear MRI Kit underwent verification testing of the MRI Kit when used at 1.5T with Osia implants, and underwent summative usability testing to evaluate the usability of the MRI Kit and accompanying documentation by specialized healthcare professionals.
The results demonstrate the updated Osia 2 System, including the modified OSI200 Implant, Osia 2 Sound Processor, and Osia Fitting Software 2 and new Cochlear MRI Kit, are functionally equivalent to the cleared Osia 2 System.
L. Conclusion
Based on the indications for use, technological characteristics, and substantial equivalence comparison to the predicate device, supported by non-clinical data, the updated Cochlear Osia 2 System has been shown to be as safe and as effective for its intended use as the predicate device.